# Slingshot Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/slingshot-biosciences

- Industry: Biotechnology
- Headquarters: Emeryville, US
- Website: www.slingshotbio.com
- Total disclosed funding: $47M
- Latest round: Series A (Jan 24, 2023)
- Investors on record: 3

## About

Slingshot Biosciences, Inc. is a biotechnology firm specializing in precision-engineered cell mimics that serve as vital tools for assay validation and quality assurance in life sciences, particularly in cancer research and diagnostics.Founded in 2012 and headquartered in Emeryville, US, Slingshot Biosciences, Inc. develops precision-engineered cell mimics. The company has not undergone any significant pivots or changes and operates independently. Charles Johnson, the founder, has grown the company through strategic funding rounds, raising a total of USD 11.230 mn, including a recent Series A round on January 24, 2023, co-led by ARCH Venture Partners, Anterra Capital, and Northpond Ventures.Slingshot Biosciences specializes in precision-engineered cell mimics under the TruCytes™ product line, which serve as reference controls for assay validation. Their biomarker cell mimics, including ViaComp® Cell Health Controls, SpectraComp® Compensation Controls, and FlowCytes® Calibration Controls, replicate the complex functions of real cells. These offerings address challenges in quality and cost in the life sciences sector, targeting research institutions and healthcare organizations focusing on cancer research, immunology, and precision diagnostics, with distribution primarily across North America and Europe.Operating on a B2B foundation, Slingshot Biosciences provides customized solutions and off-the-shelf products within the biotechnology and pharmaceutical industries. Revenue generation is achieved through direct partnerships with research organizations and tailored orders for biomarker controls, involving variable pricing structures based on order complexity. The flagship TruCytes™ biomarker cell mimics ensure precision in assay validation and solidify the company's market position in cell-based assay solutions.In January 2023, Slingshot Biosciences, Inc. raised USD 11.230 mn in Series A funding aimed at accelerating the commercialization of its technology for cell and gene therapies. The funding will support advancements in their adoptive cell therapy and therapeutics platform, with plans for expansion into new markets by targeting specific geographic regions in North America and Europe. The focus will be on launching upcoming products designed to enhance their offerings in the life sciences sector.

## Funding rounds

- Series A, Jan 24, 2023, $11M — ARCH Venture Partners, Anterra Capital, Northpond Ventures
- Series A, Jul 22, 2021, $23M — ARCH Venture Partners, Anterra Capital, Northpond Ventures
- Series A, May 28, 2021, $12M — Northpond Ventures

## Investors

- Northpond Ventures (https://capitalatlas.ai/funds/northpond-ventures) — Series A
- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A
- Anterra Capital (https://capitalatlas.ai/funds/anterra-capital) — Series A